To include your compound in the COVID-19 Resource Center, submit it here.

Metacrine, Novo Nordisk to develop FGF1 variants

Metacrine Inc. (San Diego, Calif.) partnered with Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) to develop fibroblast growth factor 1 (FGF1) variants

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE